阿托伐他汀联合曲美他嗪对冠心病心功能不全患者心功能及炎症反应的影响

Effects of Atorvastatin Combined with Trimetazidine on Cardiac Function and Inflammatory Response in Patients with Coronary Heart Disease and Cardiac Insufficiency

目的探讨阿托伐他汀联合曲美他嗪在冠心病心功能不全患者中的治疗效果.方法选取2020年1月—2021年9月我院收治的88例冠心病心功能不全患者,以随机数字表法分成对照组与观察组,各44例.对照组采用阿托伐他汀治疗,观察组在对照组基础上加用曲美他嗪治疗.对比两组康复效果.结果观察组治疗总有效率95.45%高于对照组的81.82%,差异有统计学意义(P<0.05).治疗后,观察组左心射血分数(49.77±4.09)%高于对照组的(44.34±3.12)%,左室舒张末期内径、左室收缩末期内径分别为(48.06±3.28)mm、(43.66±4.27)mm,均短于对照组,组间差异有统计学意义(P<0.05).治疗后,观察组白细胞介素-6、超敏C反应蛋白、肿瘤坏死因子-α水平分别为(46.01±4.70)ng/L、(2.48±0.57)mg/L、(103.40±10.13)ng/L,均低于对照组的(53.66±5.06)ng/L、(3.39±0.27)mg/L、(126.84±13.27)ng/L,组间差异有统计学意义(P<0.05).两组不良反应发生率比较,差异无统计学意义(P>0.05).结论阿托伐他汀联合曲美他嗪可增强冠心病心功能不全患者的临床疗效,改善患者心功能,减轻炎症反应,且不良反应少.

Objective To investigate the therapeutic effect of atorvastatin combined with trimetazidine in patients with coronary heart disease and cardiac insufficiency.Methods A total of 88 patients with coronary heart disease and cardiac insufficiency who were treated in our hospital from January 2020 to September 2021 were selected and divided into the control group and the observation group by random number table method,with 44 cases in each group.The control group was treated with atorvastatin,and the observation group was additionally treated with trimetazidine on the basis of the control group.The rehabilitation effects of the two groups were compared.Results The total effective rate of the observation group was 95.45%higher than that of the control group,81.82%,and the difference was statistically significant(P<0.05).After treatment,the left ventricular ejection fraction in the observation group was(49.77±4.09)%higher than that in the control group(44.34±3.12)%,and the leftventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter were(48.06±3.28)mm and(43.66±4.27)mm,respectively,which were shorter than those in the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,the levels of interleukin-6,high-sensitivity Creactive protein,and tumor necrosis factor-αin the observation group were(46.01±4.70)ng/L,(2.48±0.57)mg/L,and(103.40±10.13)ng/L,respectively,the levels were lower than those of the control group(53.66±5.06)ng/L,(3.39±0.27)mg/L,and(126.84±13.27)ng/L,and the differences between the groups were statistically significant(P<0.05).Conclusion Atorvastatin combined with trimetazidine can enhance the clinical efficacy of patients with coronary heart disease and cardiac insufficiency,improve cardiac function,reduce inflammatory response,and have fewer adverse reactions.